Industry
Astria Therapeutics, Inc.
Total Trials
6
Recruiting
1
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
3(50.0%)
Phase 3
2(33.3%)
Phase 2
1(16.7%)
6Total
Phase 1(3)
Phase 3(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT05695248Phase 1Completed
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
Role: lead
NCT06842823Phase 3Recruiting
A Study of Navenibart in Participants With Hereditary Angioedema
Role: lead
NCT07204938Phase 3Enrolling By Invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Role: lead
NCT06782477Phase 1Active Not Recruiting
A Study of STAR-0310 in Healthy Adult Participants
Role: lead
NCT06007677Phase 2Active Not Recruiting
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Role: lead
NCT05477160Phase 1Completed
A Study of STAR-0215 in Healthy Adult Participants
Role: lead
All 6 trials loaded